Is tirzepatide approved for weight loss in the UK?

Demand for effective weight loss solutions has led to heightened interest in medications originally designed for other purposes, such as tirzepatide, the active ingredient in Mounjaro. Originally formulated to address type 2 diabetes, tirzepatide has garnered attention for its potential in weight management, aligning with a trend that sees the use of injectable diabetic medicines like Wegovy, developed by Novo Nordisk, for weight loss.

Much like Wegovy, which features semaglutide, tirzepatide has recently received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to aid adults with obesity in their weight loss journey.

Tirzepatide belongs to a class of drugs known as GIP/GLP-1 receptor agonists, exerting its weight loss effects by curbing appetite. For individuals with diabetes, the medication also facilitates insulin release post-meals, enhancing glucose (sugar) management within the body.

In this guide, we'll explore the essence of tirzepatide, its designated uses, approved indications in the UK, available dosage strengths, and the process of obtaining it.

The availability of tirzepatide for diabetes treatment

The National Institute for Health and Care Excellence (NICE) sanctioned the use of tirzepatide as a remedy for inadequately controlled type 2 diabetes in England and Wales, in conjunction with adopting a balanced diet and engaging in regular exercise in October 2023. Tirzepatide as a treatment for diabetes is becoming increasingly difficult to attain after it was also approved for weight loss. This is also the case with other weight loss/diabetes medications also experiencing a shortage, medications containing semaglutide (such as Wegovy and Ozempic) and liraglutide (such as Saxenda) are all under high demand. 

The availability of tirzepatide for weight loss

In November 2023, the MHRA granted approval for the use of tirzepatide as a weight loss treatment within the UK.

It should be noted that Mounjaro may not be suitable for everyone. Eligibility criteria include being either 18 years old or over the age of 18 years old, having a body mass index (BMI) of 30 or higher, or a BMI falling between 27-30 alongside weight-related health conditions like prediabetes, high blood pressure, high cholesterol, or cardiovascular issues.

Similar to its prescription for managing type 2 diabetes, Mounjaro must be used alongside a reduced-calorie diet and increased physical activity to optimise its efficacy.

Is Mounjaro licensed for diabetes or weight loss?

Previously licensed only for type 2 diabetes, Mounjaro has recently gained approval for both diabetes management and weight control when it was sanctioned by the MHRA in late 2023. It is important to note that the NHS provision of Mounjaro is restricted to addressing poorly controlled type 2 diabetes. For individuals considering using Mounjaro for weight loss purposes, a private prescription is required. You can obtain a free private prescription for Mounjaro online from UK Meds.

Is tirzepatide licensed for type 1 or type 2 diabetes?

Tirzepatide is exclusively licensed for the treatment of type 2 diabetes. The distinction between type 1 and type 2 diabetes lies in the body's insulin production. Type 1 involves insufficient insulin production, while type 2 involves your bodies insulin resistance.

Mounjaro primarily help insulin release from the pancreas, making it less effective for individuals with type 1 diabetes. However, eligibility for tirzepatide treatment in type 2 diabetes is not universal. Specific criteria must be met for its use.

Mounjaro may be recommended for managing type 2 diabetes in individuals with a BMI of 35 or higher, who also encounter psychological or medical challenges. Those with type 2 diabetes and a BMI below 35 may also receive a prescription if the use of insulin poses occupational risks due to hypoglycemia. This option is considered for individuals who could potentially experience health enhancements in other obesity-related issues through weight loss.

When Mounjaro will be available in the UK?

Mounjaro became available for weight loss in February 2024. For diabetes management, the NHS operates within a three-month timeframe to ensure tirzepatide accessibility for prescription. You can purchase Mounjaro for diabetes and weight loss from UK Meds today.

What strengths of tirzepatide will be available?

Treatment usually starts at 2.5mg once weekly for four weeks, then increases to 5mg. Your prescriber may increase the dose in 2.5mg steps, to a maximum of 15mg, depending on your response. The Mounjaro (tirzepatide) page lists every KwikPen strength.

How you will be able to get Mounjaro weight loss injections

Mounjaro is a prescription-only medicine in the UK. At UK Meds, a UK-registered prescriber reviews your online consultation to check the medicine is suitable, and if treatment is approved, a partner pharmacy dispenses it. 

Medically Reviewed by:
Dr. Alexis Missick MBChB. MRCGP
GMC reference no: 7151419
LinkedIn
Website

Sources

• GOV.UK - MHRA Authorises Diabetes Drug Mounjaro Tirzepatide for Weight Management and Weight Loss

• BBC News - Mounjaro: NHS to Offer Weight Loss 'Game-Changer' Drug

• Forbes - Mounjaro: Weight Loss Shot Goes on Sale Privately in the UK

• GOV.UK - Four-dose Mounjaro Kwikpen Approved by MHRA for Diabetes and Weight Management

• NICE - NICE Committee Recommends Tirzepatide as New Treatment Option for People with Type 2 Diabetes